Acute and Long‑Term Management of Hyperkalemic Periodic Paralysis

Acute Attack Management

Intravenous glucose‑insulin therapy rapidly lowers serum potassium by shifting it intracellularly within 30–60 minutes in patients with severe weakness – recommended by the Mayo Clinic based on clinical experience. 1
Nebulized salbutamol (≈20 mg) can be added to enhance intracellular potassium redistribution during an acute paralytic episode – supported by the Mayo Clinic case series. 1
Continuous electrocardiographic monitoring is advised because hyperkalemia may precipitate arrhythmias even in HyperPP patients – emphasized by both the Mayo Clinic and the European Society of Cardiology. [1][2]

Potassium‑sparing diuretics and renin‑angiotensin system blockers (ACE inhibitors or ARBs) should be avoided, as they can worsen hyperkalemia – guideline from the Mayo Clinic. 1

Serum potassium should be measured 2–4 times per year once the patient is stable on prophylactic therapy – recommendation of the European Society of Cardiology. 3
Prophylactic therapy must be continued indefinitely; discontinuation during asymptomatic periods leads to recurrence of attacks – evidence from the European Society of Cardiology. 3

The glucose‑insulin and salbutamol recommendations are based on clinical case series and expert consensus (Mayo Clinic).
Cardiac monitoring and avoidance of potassium‑sparing agents are supported by observational data and expert opinion (Mayo Clinic).
Monitoring frequency and the need for continuous prophylaxis are derived from prospective cohort observations (European Society of Cardiology).